Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Prostate Cancer

Free Subscription 31.08.2026 3 BJU Int 4 Int J Urol 1 J Magn Reson Imaging 2 J Urol 2 Lancet Oncol 1 Oncol Rep 1 PLoS One 3 Prostate 1 Urol Int 1 Urology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

BJU Int

1. 
   Correction to "Active surveillance for patients with prostate cancer aged >/=75 years: the Prostate Cancer Research International: Active Surveillance (PRIAS)-JAPAN study".
   BJU Int. 2026 Aug 26. doi: 10.1111/bju.70437.
   PubMed        
   
   
2. LA MURA R, Maiolino G, Anract J, Valerio M, et al
   Identifying the ideal candidate for irreversible electroporation in localized prostate cancer: a comprehensive narrative review from the EAU Section of Endourology.
   BJU Int. 2026 Aug 26. doi: 10.1111/bju.70436.
   PubMed         Abstract available
   
   
3. HESS-BUSCH Y, Darr C, Pullen L, Al-Nader M, et al
   Sexual function after prostate cancer surgery or radiotherapy in an international registry.
   BJU Int. 2026 Aug 26. doi: 10.1111/bju.70431.
   PubMed         Abstract available
   
   

   
   Int J Urol

4. NUKAYA T, Naiki T, Watanabe H, Nakane K, et al
   Real-World Outcomes of Olaparib in Japanese Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer: Exploratory Analysis of BRCA2 Loss and Microsatellite Instability Status.
   Int J Urol. 2026;33:e70626.
   PubMed         Abstract available
   
   
5. IWAMOTO H, Izumi K, Machioka K, Toriumi R, et al
   Stage-Specific Temporal Trends in Treatment Patterns and Overall Survival in Prostate Cancer: A Multicentre Real-World Cohort Study From KAMU-ON.
   Int J Urol. 2026;33:e70617.
   PubMed         Abstract available
   
   
6. UTSUMI T
   Editorial Comment on Exploratory Time-Dependent Patterns in Estimated Treatment Effect of Talazoparib Plus Enzalutamide in HRR Non-Deficient or Unknown Metastatic Castration-Resistant Prostate Cancer: A Post Hoc Analysis of the TALAPRO-2 Trial.
   Int J Urol. 2026;33:e70615.
   PubMed        
   
   
7. YOSHIDA S, Fujii Y
   Editorial Comment on [(18)F]PSMA-1007 PET-Based Recurrence Site Distribution and Predictors of Metastatic Disease in Patients With Biochemical Recurrence of Prostate Cancer.
   Int J Urol. 2026;33:e70616.
   PubMed        
   
   

   
   J Magn Reson Imaging

8. CHANG H, Dai Z, Cheng H, Ji H, et al
   Accuracy of Quantitative Chemical-Exchange-Saturation-Transfer Imaging for Grading Prostate Cancer and Predicting Adverse Pathology.
   J Magn Reson Imaging. 2026 Aug 26. doi: 10.1002/jmri.70512.
   PubMed         Abstract available
   
   

   
   J Urol

9. SCARPATO KR, Cookson MS, Dreicer R, Sayan M, et al
   Reply: Advanced Prostate Cancer: AUA/SUO Guideline Amendment (2026) Part I.
   J Urol. 2026 Aug 25:101097JU0000000000005260. doi: 10.1097/JU.0000000000005260.
   PubMed        
   
   
10. FLORES JM, Kim D, Yu R, Vertosick EA, et al
    TESTOSTERONE THERAPY IN MEN ON ACTIVE SURVEILLANCE FOR PROSTATE CANCER IS NOT ASSOCIATED WITH INCREASED RISK OF DISEASE PROGRESSION.
    J Urol. 2026 Aug 24:101097JU0000000000005276. doi: 10.1097/JU.0000000000005276.
    PubMed         Abstract available
    
    

    
    Lancet Oncol

11. HENNEQUIN C, Sargos P, Roca L, Silva M, et al
    High-dose radiotherapy in patients with high-risk prostate cancers treated with long-term androgen deprivation therapy (GETUG AFU 18): a randomised, phase 3 trial.
    Lancet Oncol. 2026;27:1158-1167.
    PubMed         Abstract available
    
    
12. SEIBERT TM
    Radiotherapy dose intensification for high-risk prostate cancer-what is gained?
    Lancet Oncol. 2026;27:1060-1062.
    PubMed        
    
    

    
    Oncol Rep

13. WANG P, Li X, Ma T, Mi J, et al
    Decoding the metabolic?immune crosstalk: The role of glutamine and ammonium reprogramming in prostate cancer immune evasion (Review).
    Oncol Rep. 2026;56:180.
    PubMed         Abstract available
    
    

    
    PLoS One

14. LI Y, Chen Q, Chen H, Chen Y, et al
    Prehabilitation models in patients undergoing radical prostatectomy: A scoping review.
    PLoS One. 2026;21:e0356745.
    PubMed         Abstract available
    
    

    
    Prostate

15. DOGAN MA, Saygin H, Asdemir A, Karaca I, et al
    Comparison of Whole-Gland and Transition Zone PSA Density in Predicting Clinically Significant Prostate Cancer in PI-RADS 3 Lesions.
    Prostate. 2026 Aug 23. doi: 10.1002/pros.70237.
    PubMed         Abstract available
    
    
16. KOGUCHI D, Tsumura H, Tabata KI, Satoh T, et al
    Prognostic Impact of the Addition of Prostate-Directed Radiotherapy With or Without Metastasis-Directed Radiotherapy Under Upfront Doublet Therapy for High-Volume Metastatic Hormone-Sensitive Prostate Cancer.
    Prostate. 2026 Aug 23. doi: 10.1002/pros.70238.
    PubMed         Abstract available
    
    
17. GOUVEIA AG, Tao J, Pond G, Dong K, et al
    Stereotactic Prostate Cancer Ablative Re-Irradiation: A Systematic Review and Meta-Analysis (SPARE).
    Prostate. 2026 Aug 23. doi: 10.1002/pros.70233.
    PubMed         Abstract available
    
    

    
    Urol Int

18. BICAKLIOGLU F, Akyol Y, Mert MS, Eryildirim B, et al
    Gleason 6 Prostate Cancer: Predictors of Upgrading in a High-Volume Turkish Tertiary Center.
    Urol Int. 2026 Aug 28:1. doi: 10.1159.
    PubMed         Abstract available
    
    

    
    Urology

19. CHE R, Milton A, Simpson R, Akbar Z, et al
    Sexual Orientation and Healthcare Access Factors Associated With Prostate-specific Antigen Screening in the United States.
    Urology. 2026;214:80-86.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum